On June 22, 2026, Vigo MD — a men's telehealth startup founded by Brayden Zoucha — announced the nationwide launch of an online platform for erectile dysfunction treatment, joining an already crowded field led by Hims, Ro, and BlueChew. The company bundles licensed medical evaluations, prescription treatment, ongoing provider oversight, and discreet medication delivery into a single direct-to-consumer flow, with patients beginning at a confidential online assessment reviewed by licensed clinicians before any prescription is issued.

Why It Matters

The ED telehealth segment is one of the most commercially proven corners of sex tech, but it is increasingly defined by a handful of scaled incumbents. New entrants like Vigo MD test whether product differentiation — daily-plus-on-demand bundles, novel dosing formats — can carve share against giants competing largely on brand and price. For investors and operators, it's a signal that the men's sexual-health funnel still has room for format innovation even as the platform layer consolidates.

What sets Vigo MD apart from single-pill rivals is its dual-format flagship program. Rather than focus on one as-needed medication, the company pairs "Vital Chew," a daily prescription gum positioned for ongoing "performance readiness," with "V3," a fast-acting dissolvable intended for on-demand use. The combination is pitched as offering greater spontaneity and flexibility than the standard as-needed-only model — a play that mirrors the broader telehealth shift toward daily-dosing and novel delivery formats (chewables, dissolvable films, sprays) over traditional sildenafil and tadalafil tablets.

"Men's sexual wellness has been underserved for too long," Zoucha said in the announcement. "We created Vigo MD to make high-quality care more accessible, more convenient, and more personalized." Medications ship in discreet packaging, eliminating in-person appointments and pharmacy visits.

The launch lands in a maturing but consolidating market. ED telehealth has become a beachhead category for the largest players — Hims & Hers is expanding internationally via its $1.15B Eucalyptus acquisition, while Ro and Amazon One Medical have been waging GLP-1 price wars that pressure the entire DTC men's-health stack. A new niche entrant betting on differentiated delivery formats rather than price is a notable counter-strategy, though Vigo MD will face the same regulatory scrutiny around compounded and novel formulations that has dogged the category.

Sources

Update — 2026-06-26

Initial entry — story first created.